Peer-reviewed veterinary case report
Dog with skin T-cell lymphoma treated with oclacitinib for 3 months
By Aslan, Jeylan et al.·Published in Veterinary Dermatology·2021·Dermatology for Animals 263 Appleby Road Stafford Heights QLD 4053 Australia, Australia·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment of canine cutaneous epitheliotropic T‐cell lymphoma with oclacitinib: a case report
- Species:
- dog
Plain-English summary
A 9-year-old Staffordshire bull terrier was diagnosed with a type of skin cancer called cutaneous epitheliotropic T-cell lymphoma (CETL), which usually has a poor outlook. The dog was treated with a medication called oclacitinib, given twice daily. After starting the treatment, the dog showed some improvement, with the cancer partially going into remission for three months. While this case shows promise, more research is needed to find the best ways to treat this condition.
People also search for: dog skin cancer treatment · Staffordshire bull terrier lymphoma · oclacitinib for dogs
Abstract
Canine cutaneous epitheliotropic T‐cell lymphoma (CETL) is associated with a poor prognosis and without consistently beneficial treatment options. This case report describes a 9‐year‐old Staffordshire bull terrier with CETL treated with oclacitinib (0.7 mg/kg twice daily), resulting in partial remission that was maintained for three months. Further studies are warranted.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/vde.12976